^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + Truqap (capivasertib) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
Published date:
06/12/2020
Excerpt:
Among the 25 (44.6%) patients who achieved clinical benefit (RECIST CR/PR or SD≥4 months), 14 (56%) patients had germline BRCA1 or BRCA2 mutations (ovarian cancer (n=7), breast cancer (n=5) and castration-resistant prostate cancer (CRPC; n=2))…Seven (63.6%) of these 11
patients with germline BRCA1/2 mutant ovarian cancer achieved clinical benefit for a
median duration of response of 24 weeks (range 11.3 – 115.0); 6 of these 7 patients
were platinum-resistant.
DOI:
10.1158/2159-8290.CD-20-0163
Trial ID:
